New drug combo tested to fight tuberculosis
NCT ID NCT04550832
Summary
This study tested if adding a new drug called delpazolid to a standard three-drug tuberculosis (TB) treatment was safe and effective. It involved 76 adults with newly diagnosed, drug-sensitive lung TB. Researchers compared different doses of the new combination to the standard treatment alone over 16 weeks to see how well it cleared the TB bacteria.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical HIV Research Unit (CHRU) University of the Witwatersrand
Johannesburg, 2092, South Africa
-
Ifakara Health Institute
Bagamoyo, Tanzania
-
Ki'bongoto Infectious Disease Hospital (KIDH) Kilimanjaro Clinical Research Institute (KCRI)
Moshi, Tanzania
-
National Institute for Medical Research (NIMR-MMRC)
Mbeya, Tanzania
-
The Aurum Institute Tembisa Clinical Research Centre
Tembisa, Gauteng, 1632, South Africa
Conditions
Explore the condition pages connected to this study.